OCUL stock news
This page provides real-time market news, earnings updates, and company announcements related to Ocular Therapeutix, Inc. (OCUL).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-04 13:11 EST
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Finviz2026-02-18 13:33:35
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
Finviz2026-02-18 17:27:44
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Finviz2026-02-19 12:03:41
Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)
Finviz2026-02-19 14:54:43
What To Expect From Elanco's (ELAN) Q4 Earnings
Finviz2026-02-23 03:09:08
Ocular Therapeutix to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
Finviz2026-02-23 12:03:47
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
Finviz2026-02-23 16:03:11
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-02-23 21:33:11
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-02-24 12:09:09
Ocular Therapeutix to Participate in March Investor Conferences
Finviz2026-02-24 12:03:59
Ocular Therapeutix to Participate in March Investor Conferences
Finviz2026-02-24 12:03:59
Surrozen to Present at Upcoming Healthcare Investor Conference
Finviz2026-02-25 21:09:42
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-02-26 12:03:47
Tarsus to Participate in Upcoming Investor Conferences
Finviz2026-02-26 21:33:52
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Finviz2026-02-27 15:12:47
1 Russell 2000 stock that deserves your attention and 2 we choose to steer clear of
101 finance2026-02-27 17:00:15
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why
Finviz2026-02-27 21:39:46
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
Finviz2026-02-28 14:33:46
Harrow, Inc. (HROW): A Bull Case Theory
Finviz2026-02-28 14:33:46
FactSet Research Systems Inc. (FDS): A Bull Case Theory
Finviz2026-02-28 18:54:36
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema
Finviz2026-03-02 12:03:45
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Finviz2026-03-02 21:09:42
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Finviz2026-03-03 12:04:17
argenx Shares Dip 1.06% Amid $340M Volume Surge Ranking 415th in Daily Trading Activity
101 finance2026-03-04 00:30:57
What To Expect From Elanco's (ELAN) Q4 Earnings
Finviz2026-02-23 03:09:08
Ocular Therapeutix to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
Finviz2026-02-23 12:03:47
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
Finviz2026-02-23 16:03:11
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-02-23 21:33:11
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-02-24 12:09:09
Ocular Therapeutix to Participate in March Investor Conferences
Finviz2026-02-24 12:03:59
Ocular Therapeutix to Participate in March Investor Conferences
Finviz2026-02-24 12:03:59
Surrozen to Present at Upcoming Healthcare Investor Conference
Finviz2026-02-25 21:09:42
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-02-26 12:03:47
Tarsus to Participate in Upcoming Investor Conferences
Finviz2026-02-26 21:33:52
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
Finviz2026-02-27 15:12:47
1 Russell 2000 stock that deserves your attention and 2 we choose to steer clear of
101 finance2026-02-27 17:00:15
Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why
Finviz2026-02-27 21:39:46
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory
Finviz2026-02-28 14:33:46
Harrow, Inc. (HROW): A Bull Case Theory
Finviz2026-02-28 14:33:46
FactSet Research Systems Inc. (FDS): A Bull Case Theory
Finviz2026-02-28 18:54:36
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU for the Treatment of Diabetic Macular Edema
Finviz2026-03-02 12:03:45
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Finviz2026-03-02 21:09:42
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Finviz2026-03-03 12:04:17
argenx Shares Dip 1.06% Amid $340M Volume Surge Ranking 415th in Daily Trading Activity
101 finance2026-03-04 00:30:57
OCUL stock chart
OCUL stock detailsOCUL stock price change
On the last trading day, OCUL stock closed at 10.98 USD, with a price change of 22.82% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more